UK Markets closed

Xvivo Perfusion AB (publ) (0RKL.L)

LSE - LSE Delayed price. Currency in SEK
Add to watchlist
236.50-20.50 (-7.98%)
At close: 05:53PM BST
Currency in SEK

Valuation measures4

Market cap (intra-day) N/A
Enterprise value N/A
Trailing P/E N/A
Forward P/E N/A
PEG ratio (5-yr expected) N/A
Price/sales (ttm)N/A
Price/book (mrq)N/A
Enterprise value/revenue N/A
Enterprise value/EBITDA N/A

Trading information

Stock price history

Beta (5Y monthly) 1.71
52-week change 3N/A
S&P500 52-week change 3N/A
52-week high 3255.50
52-week low 3236.50
50-day moving average 3N/A
200-day moving average 3N/A

Share statistics

Avg vol (3-month) 3N/A
Avg vol (10-day) 3N/A
Shares outstanding 526.4M
Implied shares outstanding 6N/A
Float 823.27M
% held by insiders 112.28%
% held by institutions 157.56%
Shares short 4N/A
Short ratio 4N/A
Short % of float 4N/A
Short % of shares outstanding 4N/A
Shares short (prior month ) 4N/A

Dividends & splits

Forward annual dividend rate 4N/A
Forward annual dividend yield 4N/A
Trailing annual dividend rate 3N/A
Trailing annual dividend yield 3N/A
5-year average dividend yield 4N/A
Payout ratio 4N/A
Dividend date 3N/A
Ex-dividend date 4N/A
Last split factor 2N/A
Last split date 3N/A

Financial highlights

Fiscal year

Fiscal year ends 31 Dec 2021
Most-recent quarter (mrq)31 Mar 2022

Profitability

Profit margin 2.35%
Operating margin (ttm)-2.49%

Management effectiveness

Return on assets (ttm)-0.34%
Return on equity (ttm)0.59%

Income statement

Revenue (ttm)292.72M
Revenue per share (ttm)10.08
Quarterly revenue growth (yoy)58.90%
Gross profit (ttm)188.28M
EBITDA 386k
Net income avi to common (ttm)6.88M
Diluted EPS (ttm)-0.82
Quarterly earnings growth (yoy)-21.00%

Balance sheet

Total cash (mrq)339.78M
Total cash per share (mrq)11.52
Total debt (mrq)5.14M
Total debt/equity (mrq)0.40
Current ratio (mrq)7.08
Book value per share (mrq)35.22

Cash flow statement

Operating cash flow (ttm)-31.73M
Levered free cash flow (ttm)-124.47M